Ellen M. Daley, Cheryl A. Vamos, Gregory D. Zimet, Zeev Rosberger, Erika L. Thompson, Laura Merrell
In the article, the authors discuss developments in the prevention of human papillomavirus (HPV)-related cancers in the U.S. as of mid-2016, particularly the approval of a nine-valent HPV vaccines. They cite that the vaccines provide protection against five additional oncogenic HPV types and reverse the feminization of HPV. Also cited are the variability in vaccination rates among age groups and genders and the effectiveness of Papanicolau test screening in HPV cancer prevention.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados